ABSTRACT
UNLABELLED: DIAMOND: multicenter, 24-week, randomized trial investigating the effect of different once-daily, prolonged-release tacrolimus dosing regimens on renal function after de novo liver transplantation. Arm 1: prolonged-release tacrolimus (initial dose 0.2mg/kg/day); Arm 2: prolonged-release tacrolimus (0.15-0.175mg/kg/day) plus basiliximab; Arm 3: prolonged-release tacrolimus (0.2mg/kg/day delayed until Day 5) plus basiliximab. All patients received MMF plus a bolus of corticosteroid (no maintenance steroids). PRIMARY ENDPOINT: eGFR (MDRD4) at Week 24. Secondary endpoints: composite efficacy failure, BCAR and AEs. Baseline characteristics were comparable. Tacrolimus trough levels were readily achieved posttransplant; initially lower in Arm 2 versus 1 with delayed initiation in Arm 3. eGFR (MDRD4) was higher in Arms 2 and 3 versus 1 (p = 0.001, p = 0.047). Kaplan-Meier estimates of composite efficacy failure-free survival were 72.0%, 77.6%, 73.9% in Arms 1-3. BCAR incidence was significantly lower in Arm 2 versus 1 and 3 (p = 0.016, p = 0.039). AEs were comparable. Prolonged-release tacrolimus (0.15-0.175mg/kg/day) immediately posttransplant plus basiliximab and MMF (without maintenance corticosteroids) was associated with lower tacrolimus exposure, and significantly reduced renal function impairment and BCAR incidence versus prolonged-release tacrolimus (0.2mg/kg/day) administered immediately posttransplant. Delayed higher-dose prolonged-release tacrolimus initiation significantly reduced renal function impairment compared with immediate posttransplant administration, but BCAR incidence was comparable.
Subject(s)
Graft Rejection/drug therapy , Graft Survival/physiology , Immunosuppressive Agents/therapeutic use , Liver Diseases/surgery , Liver Transplantation , Liver/physiology , Tacrolimus/therapeutic use , Female , Follow-Up Studies , Glomerular Filtration Rate , Graft Rejection/pathology , Humans , Kidney Function Tests , Liver Diseases/physiopathology , Male , Middle Aged , Postoperative Complications , Prognosis , Risk FactorsABSTRACT
Over the past decade, we have seen an increased number of patients living more than 20 years with their liver grafts. In turn, we are gaining more experience with recurrence of the original disease. Disease recurrence can be divided into 4 main groups: (1) malignant disease, (2) viral disease, (3) autoimmune diseases like primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSO), and finally (4) researched lifestyle that caused the original disease, eg, obesity causing nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), or alcoholic liver disease (ALD). This overview reports follow up, diagnosis, and treatment of recurrences.
Subject(s)
Liver Diseases/surgery , Liver Transplantation , Humans , Liver Diseases/physiopathology , RecurrenceABSTRACT
INTRODUCTION: The introduction of hepatitis B immunoglobulin (HBIG) in the early 1990s dramatically reduced recurrence of hepatitis B after orthotopic liver transplantation (OLT) and thus improved survival. Today a combination of HBIG and a nucleoside or nucleotide analogue (NUC) is recommended as prophylaxis. The optimal protocol is yet to be commonly agreed upon. The aim of this study was to review our results over 25 years. PATIENTS AND METHODS: All 56 patients (45 males and 11 females) who underwent OLT due to hepatitis B infection between 1985-2009 were included in the review. Median age at transplantation was 51 years (range, 18-66). Seventeen patients (30%) had hepatocellular carcinoma (HCC) at transplantation. RESULTS: The 1- and 5-year overall survival rates were 89% and 77%, respectively. The 23 patients who underwent transplantation before 2000 showed 1- and 5-year survival rates of 82% and 61%, respectively; the 33 who underwent transplantation between 2000 and 2009, the rates were 94% and 90%, respectively (P < .01). There was no difference in the 5-year survival rate between patients who had or did not have been HCC (75% vs 78%, respectively). Recurrence of hepatitis B, defined as seroconversion to HBsAg positivity, was observed in 9 patients. Three transplantation cases before 1992 consequently did not receive HBIG. The remaining 6, who all underwent OLT between 1993 and 2001, were administered HBIG. In all 6 cases periods of low anti-HBs titers were registered prior to recurrence; treating physician noncompliance with the protocol may have contributed to the low anti-HBs titers. No recurrence was registered after 2001. CONCLUSION: With a combination of HBIG and NUC, excellent OLT results can be achieved for hepatitis B. It is, however, still important to maintain sufficient anti-HBs titers to prevent recurrence.
Subject(s)
Antiviral Agents/administration & dosage , Guideline Adherence , Hepatitis B/physiopathology , Liver Transplantation , Adolescent , Adult , Aged , Clinical Protocols , Female , Hepatitis B/prevention & control , Humans , Immunoglobulins/administration & dosage , Male , Middle Aged , Nucleosides/administration & dosage , Nucleotides/administration & dosage , Recurrence , Retrospective Studies , Survival Rate , Young AdultABSTRACT
BACKGROUND: Our program for ABO-incompatible renal transplantation includes antigen-specific immunoadsorption (extracorporeal columns with the A or B trisaccharides), rituximab, and standard maintenance immunosuppression. Anti-A or -B titers ≤ 8 in the indirect antiglobulin test (IAT) against panel A1 or B RBC are acceptable for transplantation. CASE REPORT: A previously healthy, 15-month-old girl was diagnosed with Wilms' tumor and proteinuria. Denys-Drash syndrome was confirmed. Bilateral nephrectomy was performed. At 3.5 years of age she received an ABO-incompatible renal transplant from her father (A1 to O). The anti-A titers before transplantation were low. She was treated preoperatively with rituximab, immunoadsorption, immunoglobulin and mycophenolate mofetil (MMF). The maintenance immunosuppression protocol included basiliximab, tacrolimus, MMF, and prednisolone. The initial postoperative course was uncomplicated with rapid normalization of serum creatinine. The anti-A titers started to increase on postoperative day 5 (8 NaCl/16 IAT). Despite daily immunoadsorptions the titers rose to 1024 NaCl/1024 IAT on day 9. Renal function deteriorated and hemodialysis was started. A renal biopsy on day 9 showed acute severe antibody-mediated rejection. Additional treatment with bortezomib was given and after 2 doses the titers started to decline, renal allograft function improved and hemodialysis was stopped. On day 21 posttransplant the titers went down, creatinine was 28 µmol/L, and no more immunoadsorptions were performed. CONCLUSION: By using bortezomib, we were able to successfully reverse a severe ABO antibody-mediated rejection.
Subject(s)
ABO Blood-Group System/immunology , Boronic Acids/therapeutic use , Graft Rejection/prevention & control , Kidney Transplantation/immunology , Pyrazines/therapeutic use , Bortezomib , Female , Graft Rejection/immunology , Humans , Infant , Wilms Tumor/surgeryABSTRACT
Polyomavirus BK (BKV)-associated nephropathy causes premature kidney transplant (KT) failure. BKV viruria and viremia are biomarkers of disease progression, but associated risk factors are controversial. A total of 682 KT patients receiving basiliximab, mycophenolic acid (MPA), corticosteroids were randomized 1:1 to cyclosporine (CsA) or tacrolimus (Tac). Risk factors were analyzed in 629 (92.2%) patients having at least 2 BKV measurements until month 12 posttransplant. Univariate analysis associated CsA-MPA with lower rates of viremia than Tac-MPA at month 6 (10.6% vs. 16.3%, p = 0.048) and 12 (4.8% vs. 12.1%, p = 0.004) and lower plasma BKV loads at month 12 (3.9 vs. 5.1 log(10) copies/mL; p = 0.028). In multivariate models, CsA-MPA remained associated with less viremia than Tac-MPA at month 6 (OR 0.60; 95% CI 0.36-0.99) and month 12 (OR 0.33; 95% CI 0.16-0.68). Viremia at month 6 was also independently associated with higher steroid exposure until month 3 (OR 1.19 per 1 g), and with male gender (OR 2.49) and recipient age (OR 1.14 per 10 years) at month 12. The data suggest a dynamic risk factor evolution of BKV viremia consisting of higher corticosteroids until month 3, Tac-MPA compared to CsA-MPA at month 6 and Tac-MPA, older age, male gender at month 12 posttransplant.
Subject(s)
BK Virus/physiology , Cyclosporine/therapeutic use , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/adverse effects , Tacrolimus/therapeutic use , Virus Replication , Adult , Female , Humans , Male , Middle Aged , Prospective StudiesABSTRACT
Sotrastaurin, a selective protein-kinase-C inhibitor, blocks early T-cell activation through a calcineurin-independent mechanism. In this study, de novo renal transplant recipients with immediate graft function were randomized 1:2 to tacrolimus (control, n = 44) or sotrastaurin (300 mg b.i.d.; n = 81). All patients received basiliximab, mycophenolic acid (MPA) and steroids. The primary endpoint was the composite of treated biopsy-proven acute rejection (BPAR), graft loss, death or lost to follow-up at month 3. The main safety assessment was estimated glomerular filtration rate (eGFR); modification of diet in renal disease (MDRD) at month 3. Composite efficacy failure at month 3 was higher for the sotrastaurin versus control regimen (25.7% vs. 4.5%, p = 0.001), driven by higher BPAR rates (23.6% vs. 4.5%, p = 0.003), which led to early study termination. Median (± standard deviation [SD]) eGFR was higher for sotrastaurin versus control at all timepoints from day 7 (month 3: 59.0 ± 22.3 vs. 49.5 ± 17.7 mL/min/1.73 m(2) , p = 0.006). The most common adverse events were gastrointestinal disorders (control: 63.6%; sotrastaurin: 88.9%) which led to study-medication discontinuation in two sotrastaurin patients. This study demonstrated a lower degree of efficacy but better renal function with the calcineurin-inhibitor-free regimen of sotrastaurin+MPA versus the tacrolimus-based control. Ongoing studies are evaluating alternative sotrastaurin regimens.
Subject(s)
Kidney Transplantation/physiology , Protein Kinase C/antagonists & inhibitors , Pyrroles/therapeutic use , Quinazolines/therapeutic use , Adult , Calcineurin Inhibitors , Female , Humans , Male , Mycophenolic Acid/therapeutic use , Tacrolimus/therapeutic useABSTRACT
The treatment for cholangiocarcinoma (CCA) remains a challenge because of the aggressive nature of the disease and the absence of effective treatments besides surgical resection (HR) and liver transplantation (LT). In intrahepatic CCA, HR remains the treatment of choice whereas with concomitant liver disease such as cirrhosis or primary sclerosing cholangitis (PSC), LT is the only option. Hilar CCA or Klatskin tumours have in recent decades been managed with a more aggressive surgical approach to achieve R0 resection. This approach usually involves preoperative portal embolisation, followed by liver resection sometimes extensive and even with portal vein resection. The recent protocols that combine preoperative neoadjuvant chemoirridation and LT show promising results that need to be confirmed. The development of diagnostic modalities (tumour markers, cytology and radiology) are of the utmost importance to identify these patients at an early stage to preserve radical surgery possible. Cholangiocarcinoma (CCA) is a malignant disease of the epithelial cells in the intra- and extrahepatic bile ducts. While still a rare malignant disease, CCA is the second most common primary malignancy of the liver. The incidence is increasing; especially the incidence of intrahepatic CCA (1). The treatment of CCA is challenging as it is usually difficult to diagnose when radical surgical treatment, resection (HR) or liver transplantation (LT) is possible. The lack of effective medical treatment makes a radical surgical resection or hepatectomy the only therapeutic option. Most of the CCAs are unresectable at presentation and the prognosis for these patients is dismal.
Subject(s)
Bile Duct Neoplasms/surgery , Bile Ducts, Intrahepatic , Cholangiocarcinoma/surgery , Bile Duct Neoplasms/classification , Bile Duct Neoplasms/epidemiology , Cholangiocarcinoma/epidemiology , Hepatic Duct, Common , Humans , Klatskin Tumor/classification , Klatskin Tumor/surgery , Liver Transplantation , Risk FactorsABSTRACT
The limiting factor in organ transplantation is the availability of organs. Ongoing work to improve donation rates both at the public and the organizational level in donating hospitals is essential. We also think that encouragement of live donation is important, and the possibility of ABO incompatible transplantation has increased the number of LD transplantations. The one-year graft survival rate is excellent and focus has shifted towards achieving long-term results to reduce the attrition rate. There is also an increasing interest in studying and working to reduce comorbidities on a long-term basis and thus, improve survival rates and recipient quality of life.
Subject(s)
Hospitals, University , Kidney Transplantation , Tissue Donors/supply & distribution , ABO Blood-Group System/immunology , Adolescent , Adult , Aged , Blood Group Incompatibility/immunology , Child , Donor Selection , Female , Graft Rejection/immunology , Graft Rejection/prevention & control , Graft Survival , Histocompatibility , Humans , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/adverse effects , Kidney Transplantation/immunology , Kidney Transplantation/mortality , Male , Middle Aged , Program Evaluation , Sweden , Time Factors , Tissue and Organ Procurement , Treatment Outcome , Young AdultABSTRACT
INTRODUCTION: Cold ischemia time (CIT) influences long-term graft survival after deceased donor (DD) kidney transplantation. The aim of the present study was to identify factors that influenced CIT at our institution, seeking to lay ground for improvement. PATIENTS AND METHODS: Patients who underwent DD kidney transplantations from November 2008 to April 2009 were included in the study. In a prospective protocol the times for various events were registered. The 40 DD kidney transplantations included 26 "paired" kidneys from the same donor and 14 "single" kidneys. RESULTS: The mean CIT was 15.2 hours ± 4.2 hours (range, 7.0-23.9). "First kidney" was 13.3 hours ± 3.4 versus 19.2 ± 2.8 hours for the "second kidney" (P < .001). The waiting time for the operating room (OR) was 2.4 hours (range, 0-12 hours). Twenty-five percent of the patients waited more than 4 hours. Patients arriving at the hospital at the same time as or before the kidney retrieval showed a CIT of 13.4 ± 3.9 hours compared with 17.4 ± 3.4 hours for patients that arrived after the retrieved kidney (P < .01). CONCLUSION: We identified factors influencing CIT that could lay the foundation for improvement. An extended cooperation and exchange with another transplantation unit for the "second kidney" could reduce the CIT. To reduce the waiting time for OR at the hospital to less than 2 hours and to get the recipient into the hospital before the kidney arrives are efforts that could reduce CIT.
Subject(s)
Cold Temperature , Ischemia , Kidney Transplantation , Kidney/blood supply , Humans , Sweden , Time and Motion StudiesABSTRACT
BACKGROUND: Chronic kidney disease (CKD) has emerged as a significant cause of morbidity and a risk factor for mortality after orthotopic liver transplantation (OLT). The use of calcineurin inhibitor (CNI)-based immunosuppression is an important etiologic factor for developing CKD. CNI discontinuation or minimization protocols with replacement of the CNI with non-nephrotoxic drugs, such as mycophenolate mofetil (MMF) or sirolimus (SRL), may have the potential to preserve or recover renal function. PATIENTS AND METHODS: In this prospective, randomized, single-center study with CNI discontinuation, OLT recipients with CKD (measured glomerular filtration rate [GFRm] 15-45 mL/min/1.73 m(2)) were randomized to either SRL or MMF-based immunosuppression. The main objective was to study the effect of CNI discontinuation on renal function. Secondary aims were to assess the frequency of biopsy-proven acute rejection episodes (BPAR) and adverse events (AE). Renal function was followed with GFRm using 51-Chromium EDTA clearance at baseline, 3 months, and 1 year. Patients were stratified according to baseline GFRm > versus <30 mL/min/1.73 m(2). The 25 patients were enrolled for MMF (n = 13) or SRL (n = 12). The median age at inclusion was 59 years (range, 25-66) and the median number of years after OLT was 4.4 (range, 1-13). Twenty-two patients were followed up for a year; MMF (n = 12) and SRL (n = 10). RESULTS: Mean GFRm for the whole cohort (n = 25) was 31+/-8 mL/min/1.73 m(2) at baseline. After 3 months the GFRm (n = 23) increased to 40+/-10 mL/min/1.73 m(2) (P = .0001) and at 1 year 42 +/- 11 mL/min/1.73 m(2) (n = 22). There was not significant difference between the MMF and the SRL study arms. The cohort (n = 8) with baseline GFRm <30 mL showed a 63% (P = .003) increased filtration after 1 year. There was no significant difference in the frequency or severity of AE between the study arms with the exception of oral ulcerations and persistent hypertriglyceridemia in the SRL group. Two deaths occurred, 1 in each study arm, both probably unrelated to the change in immunosuppression. There were no BPAR episodes. CONCLUSION: CNI discontinuation and replacement with either MMF or SRL resulted in a significant improvement in renal function even in those patients with severe CKD. The protocol was effective with no acute rejection episodes. The SRL arm showed a higher frequency of oral apthous ulcerations and hypertriglyceridemia. Future studies addressing long-term renal function after CNI discontinuation are needed.
Subject(s)
Calcineurin Inhibitors , Immunosuppressive Agents/administration & dosage , Kidney Failure, Chronic/physiopathology , Kidney/physiopathology , Liver Transplantation , Mycophenolic Acid/analogs & derivatives , Sirolimus/administration & dosage , Adult , Antihypertensive Agents/therapeutic use , Glomerular Filtration Rate , Humans , Hypertension/complications , Hypertension/drug therapy , Immunosuppressive Agents/adverse effects , Kidney Failure, Chronic/complications , Mycophenolic Acid/administration & dosage , Mycophenolic Acid/adverse effects , Prospective Studies , Sirolimus/adverse effectsABSTRACT
OBJECTIVES: At our center living donor liver transplantation (LDLT) represents 4% of all transplantations. The aim of this cross-sectional study was to clarify the current well-being of the donors, their experiences of being a donor, as well as the regenerative capacity of the liver. PATIENTS AND METHOD: Thirty-six healthy subjects donated a part of their liver between 1996 and 2007. Thirty-four patients participated in the study and completed our questionnaire. We performed magnetic resonance imaging (MRI) of the liver, physical examination, and blood chemistry. RESULTS: Twenty-three subjects had donated the left lateral segment and 11 the right lobe. Their hospital stay ranged from 5-15 days (median, 10). Mostly, the sick-leave period was 8-12 weeks and time for recovery was 3-6 months. Long-term problems were heartburn, abdominal discomfort, incisional hernia, and fatigue. Twenty-six (76.5%) subjects viewed the donation experience as entirely positive; no one was regretful. Liver function tests were normal. The MRI data at follow-up of 13 left lateral segment and 11 right lobe grafts showed recovery of the total liver volume to almost preoperative values, mean 1522 ± 241 mL versus 1552 ± 219 mL, respectively. CONCLUSION: Living liver donors commonly recovered after 3-6 months, perceiving donation as a positive experience with no regret. Durable side effects were mainly heartburn and abdominal discomfort, but the symptoms were mostly mild. Liver function was normal. The MRI data showed a mean regeneration of liver volume to 98.6% of the preoperative values.
Subject(s)
Liver Transplantation , Living Donors , Blood Chemical Analysis , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Physical ExaminationABSTRACT
BACKGROUND: We investigated whether sympathetic, noradrenergic nerves participate in experimental acute ischemia-reperfusion injury of the rat liver. METHODS: Female Wistar rats (200-250 g body weight) were anesthetized with pentobarbital. After tracheotomy, we cannulated a carotid artery and jugular vein. The rats were divided in 2 groups (n = 8 per group). The control group received NaCl IV and the test group received the sympatholytic agent, guanethidine (3 mg/kg, IV). After 30 minutes of drug equilibration, laparotomy was performed to arrange the liver for temporary occlusion (by a ligature) of its vascular supply, corresponding with 70% reduction in hepatic blood flow. The rats were then allowed 60 minutes of equilibration. Thereafter, regional ischemia was induced for 30 minutes. The animals were then monitored for 2 hours of reperfusion. Blood samples for alanine aminotransferase (ALT) estimation (as a measure of injury to the parenchyma) were drawn immediately before ischemia, as well as 60 and 120 minutes after reperfusion. Readings of mean arterial pressure were taken during these times. RESULTS: After 2 hours of reperfusion, there were no significant differences between the groups with regard to ALT or mean arterial pressure. CONCLUSION: Sympathetic, noradrenergic nerves did not affect experimental ischemia-reperfusion injury of rat liver in the current model.
Subject(s)
Liver Circulation/physiology , Liver/physiology , Reperfusion Injury/physiopathology , Reperfusion , Sympathetic Nervous System/physiology , Alanine Transaminase/blood , Animals , Blood Pressure , Female , Guanethidine/therapeutic use , Hepatocytes/physiology , Rats , Rats, Wistar , Reperfusion/methods , Sympathetic Nervous System/drug effects , Sympatholytics/therapeutic useABSTRACT
There has been a need to assess the "sickness degree" in patients with acute and chronic hepatic failure. The Model for End-Stage Liver Disease (MELD) score was developed as a tool for a more objective estimate of the "degree" of sickness in patients with chronic liver disease. In this study, the MELD score was retrospectively calculated and compared in adult patients accepted for orthotopic liver transplantation (OLT) in our institution in 1999 and 2004. We analyzed the gender, age, and MELD score associated with different indications for OLT during this period.
Subject(s)
Liver Failure/surgery , Liver Transplantation/statistics & numerical data , Patient Selection , Female , Humans , Liver Cirrhosis/surgery , Liver Neoplasms/surgery , Male , Prognosis , Reoperation/statistics & numerical data , Retrospective Studies , SwedenABSTRACT
DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C(2) Monitoring Versus Tacrolimus) was a 6-month, open-label, randomized, multicenter study which used American Diabetes Association/World Health Organization criteria to define glucose abnormalities. De novo renal transplant patients were randomized to cyclosporine microemulsion (CsA-ME, using C(2) monitoring) or tacrolimus, with mycophenolic acid, steroids and basiliximab. The intent-to-treat population comprised 682 patients (336 CsA-ME, 346 tacrolimus): 567 were nondiabetic at baseline. Demographics, diabetes risk factors and steroid doses were similar between treatment groups. The primary safety endpoint, new-onset diabetes after transplant (NODAT) or impaired fasting glucose (IFG) at 6 months, occurred in 73 CsA-ME patients (26.0%) and 96 tacrolimus patients (33.6%, p = 0.046). The primary efficacy endpoint, biopsy-proven acute rejection, graft loss or death at 6 months, occurred in 43 CsA-ME patients (12.8%) and 34 tacrolimus patients (9.8%, p = 0.211). Mean glomerular filtration rate (Cockcroft-Gault) was 63.6 +/- 20.7 mL/min/1.73 m(2) in the CsA-ME cohort and 65.9 +/- 23.1 mL/min/1.73 m(2) with tacrolimus (p = 0.285); mean serum creatinine was 139 +/- 58 and 133 +/- 57 mumol/L, respectively (p = 0.005). Blood pressure was similar between treatment groups at month 6, but total cholesterol, LDL-cholesterol and triglyceride levels were significantly higher with CsA than with tacrolimus (total cholesterol:HDL remained unchanged). The profile and incidence of adverse events were similar between treatments. The incidence of NODAT or IFG at 6 months post-transplant is significantly lower with CsA-ME than with tacrolimus without a significant difference in short-term outcome.
Subject(s)
Cyclosporine/therapeutic use , Glucose/metabolism , Kidney Transplantation/immunology , Metabolic Diseases/immunology , Tacrolimus/therapeutic use , Adolescent , Adult , Aged , Cyclosporine/adverse effects , Diabetes Mellitus/epidemiology , Diabetes Mellitus/immunology , Drug Therapy, Combination , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Metabolic Diseases/epidemiology , Middle Aged , Tacrolimus/adverse effects , Treatment OutcomeABSTRACT
Combined liver and renal transplantations can be performed against a positive cross-match, indicating that the liver protects the kidney from the harmful HLA antibodies. This led us to the hypothesis that a partial auxiliary liver graft may have a similar protective effect when performed together with the kidney in highly sensitized patients. Seven patients, with broadly reacting HLA antibodies and positive crossmatches, were transplanted with a partial liver and a kidney from the same donor. In one of the cases a living donor was used. We performed lymphocytotoxic and flow cross-matches before and after the transplantation. Cross-matches turned negative after grafting in five of seven cases. The kidney function was excellent, without rejections, during the follow-up (24-60 months) in these patients. In two cases the cross-match remained positive after transplantation, one with a never-functioning renal graft and the other with an early graft failure, probably due to humoral rejection. A simultaneous transplantation of a partial auxiliary liver graft from the same donor, with the sole purpose of protecting the kidney from harmful lymphocytotoxic antibodies, can be performed successfully despite a positive cross-match and may thus be a new option of treatment for highly sensitized patients waiting for a kidney transplant.
Subject(s)
HLA Antigens/immunology , Kidney Diseases/therapy , Kidney Transplantation/methods , Liver Transplantation/immunology , Transplantation Immunology , Adult , Antilymphocyte Serum , Female , Graft Survival , Histocompatibility Testing , Humans , Isoantibodies , Kidney Transplantation/immunology , Male , Middle Aged , Treatment OutcomeABSTRACT
The transplantation program with cadaveric organs has been ongoing at our institution for more than 40 years, since 1965. The purpose of this report was to analyze changes in the donor population and causes of death over the years. This retrospective analysis of donor records between 1977 and 2005, included 1331 donors. Since 1977, the number of donors has remained unchanged, but their profile has changed. The median donor age today has almost doubled, from 30 to nearly 60 years. Early on the most common cause of death was head trauma and the majority of donors were men. Since the mid-1980s, the main cause of death was intracerebral hemorrhage or cerebral thrombosis and the gender distribution became equal. The number of procured and transplanted organs from each donor has increased, despite an increased donor age. The multi-organ donor rate exceeded 80% in the beginning of this decade; we retrieved 3.9 organs per donor. These results may be explained by improved organ donor care and organization, and by increased awareness of potential donors among elderly patients.
Subject(s)
Tissue Donors , Tissue and Organ Procurement/organization & administration , Adolescent , Adult , Age Distribution , Aged , Cadaver , Cause of Death , Child , Female , Humans , Male , Middle Aged , Retrospective Studies , Sweden , Tissue and Organ Procurement/statistics & numerical dataABSTRACT
Renal dysfunction is a growing problem after liver, heart, or lung transplantation with the subsequent need for dialysis or renal transplantation. The aim of this study was to analyze the outcome after a subsequent kidney transplantation (secondary kidney transplantation) in liver, heart, or lung transplantation recipients. All secondary kidney transplantation patients from 1985 to 2006 were identified for the cause of kidney failure, time after initial transplantation, and current kidney function. One thousand two hundred three patient charts were reviewed including 22 (1.8%) secondary kidney transplantations: eight after lung, eight after heart, and six after liver transplantation. Renal failure was the result of perioperative renal failure (n = 3), toxic effects of cyclosporine (n = 16), a combination of cyclosporine nephrotoxicity and vascular ischemia (n = 3), or chronic renal failure due to polycystic kidney disease (n = 1). The median time after the initial organ transplantation was 114 months (range 30 to 241 months). The most recent median creatinine value was 103 micromol/L (82 to 704 micromol/L). Renal transplant rejection was noted in five patients: four in the lung transplant group, and one after heart transplantation. Three patients were deceased, one from secondary renal failure. One renal allograft was removed after renal artery thrombosis. In conclusion, there is sometimes a need for subsequent kidney transplantation after liver, heart, or lung transplantation. The outcome of renal transplantation subsequent to liver, heart, or lung transplantation is good with satisfactory renal function in this study population.
Subject(s)
Heart Transplantation , Kidney Transplantation , Liver Transplantation , Lung Transplantation , Humans , Reoperation , Retrospective Studies , Treatment Failure , Treatment OutcomeABSTRACT
In contrast to focal segmental glomerulosclerosis, which is well known to recur early in a renal graft, there are only few cases described with recurrence of immunoglobulin M (IgM) nephropathy after transplantation. We herein describe a patient with early recurrence of IgM nephropathy. A 15-year-old boy with nephrotic syndrome (IgM nephropathy) proceeding to end-stage renal disease was on dialysis before living related renal transplantation. Native kidneys were not removed. Standard immunosuppression including steroids, tacrolimus, and mycophenolate mofetil yielded initially good graft function with the s-creatinine falling to 73 micromol/L. Proteinuria was present on day 1, increasing to 20 g/L after 3 days. S-creatinine increased to 158 micromol/L and urine production diminished. A graft biopsy showed no rejection or glomerulopathy but protein vacuoles were seen within tubular cells indicating massive proteinuria. Treatment with plasma exchanges, immunoglobulin, and steroids was started. Hemodialysis was necessary. Proteinuria improved to 3.5 g/L, but s-creatinine continued to rise and a second graft biopsy showed vascular rejection (Banff type IIA). The patient was treated with antithymocyte globulin and further plasma exchanges. A single dose of rituximab was given. Five months after transplantation the s-creatinine was 67 micromol/L and there was no proteinuria. In this case early recurrence of nephrotic syndrome occurred on the first posttransplant day in combination with later occurring vascular rejection. Successful treatment included a combination of plasma exchanges, rituximab, immunoglobulin, and antithymocyte globulin.